Extent of disease impacts the effective half-life of iodine I 131 tositumomab in non-Hodgkin's lymphoma (NHL).

被引：0
|
作者：
Kostakoglu, L
Leonard, JP
Coleman, M
Tidmarsh, GF
Kroll, SM
Bhatnagar, A
Vallabhajosula, S
Goldsmith, SJ
机构：
[1] Cornell Univ, Weill Med Coll, Ctr Lymphoma & Myeloma, Div Nucl Med, Ithaca, NY 14853 USA
[2] Cornell Univ, Weill Med Coll, Ctr Lymphoma & Myeloma, Div Hematol Oncol, Ithaca, NY 14853 USA
[3] New York Presbyterian Hosp, New York, NY USA
[4] Coulter Pharmaceut Inc, S San Francisco, CA USA
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
391
引用
收藏
页码：90A / 90A
页数：1
相关论文
共 50 条
  • [1] Patient-specific characteristics correlate with the effective half-life of 131I tositumomab therapy in non-Hodgkin's lymphoma (NHL).
    Kostakoglu, L
    Leonard, JP
    Coleman, M
    Kroll, SM
    Bhatnagar, A
    Vallabhajosula, S
    Magnuson, D
    Goldsmith, SJ
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 79P - 79P
  • [2] Dosimetry of iodine I 131 tositumomab in previously untreated patients with non-Hodgkin's lymphoma (NHL).
    Zasadny, KR
    Rommelfanger, SG
    Regan, DD
    McCullough, NT
    Kroll, S
    Kaminski, MS
    Wahl, RL
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 82P - 83P
  • [3] Tumor response predictors in radioimmunotherapy of previously untreated non-Hodgkin's lymphoma (NHL) with Iodine I 131 tositumomab.
    Zasadny, KR
    Rommelfanger, SG
    Regan, DD
    McCullough, NT
    Kroll, S
    Stagg, R
    Kaminski, MS
    Wahl, RL
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 29P - 30P
  • [4] The effectiveness of tositumomab and iodine I 131 tositumomab in relapsed/refractory follicular grade 1/2 and small lymphocytic non-Hodgkin's lymphoma (NHL).
    Armitage, JO
    Leonard, JP
    Gregory, SA
    Horning, SJ
    Zelenetz, AD
    Kaminski, MS
    Fisher, RI
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 575S - 575S
  • [5] Bexxar, iodine I 131 tositumomab, effective in long term follow-up of non-Hodgkin's lymphoma
    Kaminski, Mark
    CANCER BIOLOGY & THERAPY, 2007, 6 (07) : 996 - 997
  • [6] Tositumomab and 131I therapy in non-Hodgkin's lymphoma
    Wahl, RL
    JOURNAL OF NUCLEAR MEDICINE, 2005, 46 : 128S - 140S
  • [7] Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma
    Davies, AJ
    Rohatiner, AZS
    Howell, S
    Britton, KE
    Owens, SE
    Micallef, IN
    Deakin, DP
    Carrington, BM
    Lawrance, JA
    Vinnicombe, S
    Mather, SJ
    Clayton, J
    Foley, R
    Jan, H
    Kroll, S
    Harris, M
    Amess, J
    Norton, AJ
    Lister, TA
    Radford, JA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (08) : 1469 - 1479
  • [8] Cost-effectiveness of tositumomab and iodine I-131 tositumomab (Bexxar therapeutic regimen (BTR)), in treatment of non-Hodgkin lymphoma (NHL)
    Flowers, C. R.
    Sambrook, J. C.
    Briggs, A.
    Osenenko, K.
    Wang, H.
    Dalal, M. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Iodine I 131 tositumomab for patients with follicular non-Hodgkin's lymphoma (NHL): Overall clinical trial experience by histology.
    Vose, JM
    Zelenetz, AD
    Rohatiner, A
    Knox, S
    Stagg, R
    Kroll, S
    Tidmarsh, G
    Kaminski, MS
    BLOOD, 1999, 94 (10) : 89A - 89A
  • [10] Fludarabine monophosphate followed by iodine I 131 tositumomab for untreated low-grade and follicular non-Hodgkin's lymphoma (NHL).
    Leonard, JP
    Coleman, M
    Kostakoglu, L
    Chadburn, A
    Cesarman, E
    Bhatnagar, A
    Tidmarsh, GF
    Kroll, SM
    Goldsmith, SJ
    BLOOD, 1999, 94 (10) : 90A - 90A
12345